Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: (no name provided) who wrote (1120)	3/31/1998 3:36:00 PM
From: margaret foley	Read Replies (1) \| Respond to of 1359

Old sweet refrain---Georgia On My Mind Absolutely fabulous! The news will be effective on April Fools Day!

To: (no name provided) who wrote (1120)	3/31/1998 3:55:00 PM
From: Pancho Villa	Read Replies (2) \| Respond to of 1359

>The randomized, double-blinded, multi-center study involved 1,072 patients who had been part of a trial of a new sustained release form of Redux which was never marketed.< This is a fragment from the press release: biz.yahoo.com Three questions: Does the study decrease potential liability for the patients that may show damage from the version that was marketed? Given the troublesome history of the initial approval, what are the chances the FDA ever approesl for the sustained release version. I wonder what other experts will have to say about these results. And, who paid for this study? Seems to me that if AHP/IPIC paid there is a built in bias to soften possible valve anormality reading from the electro regardless of the group. Not trying to say scientists are crooks, just human nature. Pancho PS: just a few things to consider beofre you rush out to buy some more